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Abstract 
Objective: One-third of women with epithelial 
ovarian cancer are resistant to standard 
platinum-based chemotherapy, and insufficient 
data exist in predicting response to 
chemotherapy. We describe the clinical and 
pathological factors of patients with complete 
and incomplete response to treatment. 
Method: In this retrospective study, data was 
reviewed from 75 medical charts of 243 patients 
with primary epithelial ovarian cancers as a 
preliminary study. All patients underwent 
chemotherapy and cytoreductive surgery for 
primary disease. Fifty-six patients had complete 
response (CR) to chemotherapy and 19 had 
incomplete response (IR).  Fifty-eight and 17 
patients had optimal and suboptimal 
cytoreductive surgery, respectively. Clinical and 
pathological factors were compared in patients 
with complete and incomplete response to 
treatment, and optimal and suboptimal surgery. 
Overall survival (OS), cancer-specific survival 
(CSS), and time to recurrence (TTR) were 
estimated using the Kaplan-Meier method for 
patient groups. 
Results: The majority of patients in both the CR 
and IR groups were diagnosed at advanced 
stage ovarian cancer. The CR group had 
significantly lower preoperative CA125 and was 
more likely to have optimal chemotherapy. The 
CR group was also more likely to have lymph 
nodes removed during cytoreductive surgery. A 
significantly lower percentage of CR patients 
died from the disease and had statistically 
longer disease free survival. Patients who 
underwent suboptimal surgery had significantly 
shorter survival, but no difference existed in the 
time until recurrence between patients with 
optimal and suboptimal surgery. OS, CSS, and 
TTR were significantly increased in the CR 
group and in patients that had optimal surgery.  
Conclusion: Complete response during 
treatment and optimal surgery significantly 
increases OS, CSS, and TTR. Preoperative 
CA125 and lymph node removal during surgery 
may be predictive of complete treatment 
response. 
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Introduction 
The incidence of ovarian cancer has 
decreased since the 1980s; 
nevertheless, it remains the second 
leading cause of malignancy in women 
and the leading cause of mortality from 
gynecologic cancers. Approximately 
90% of ovarian cancers are epithelial in 
nature and about 70% are diagnosed at 
advanced stage defined as International 
Federation of Gynecology and 
Obstetrics (FIGO) stage III and IV. 
Advanced stage ovarian cancer is 
associated with poor prognosis and a 5-
year survival rate of 27%.1 
The standard treatment plan for primary 
epithelial ovarian cancer (EOC) includes 
debulking surgery and platinum-based 
chemotherapy. Surgery is an important 
mainstay of treatment and has been 
shown to improve patients’ 
chemoresponsiveness and survival.2,3 
However, one-third of women are 
resistant to platinum-based therapy, 
defined as having evidence of disease 
within 6 months of treatment. 
Additionally, they have worse 
progression-free and overall survival. Up 
to 85% of advanced stage EOC relapse, 
and the median time until recurrence is 
18 months.4 
The current literature contains 
unsatisfactory data to identify 
differences between patients who are 
responsive and nonresponsive to 
standard chemotherapy. Therefore, the 
purpose of this study is to describe the 
clinical and pathological characteristics 
of patients with complete and 
incomplete response to treatment. This 
can potentially determine possible 
predictors of response. Identifying these 
predictors of chemoresponsiveness will 
be integral in individualizing treatment 
and solving the issue of 
chemoresistance. 
Materials and Methods 
Study design 
Patients with primary epithelial ovarian 
cancers diagnosed by tumor histological 
analysis and treated at the Department 
of Gynecologic Oncology at the 
University of Iowa Hospital and Clinics 
from January 1991 to December 2013 
were eligible for inclusion in this 
retrospective study. All patients 
underwent chemotherapy and surgical 
cytoreduction for primary disease.  
Institutional Review Board approval was 
obtained and a total of 243 patients 
were eligible for this study. Data was 
collected from medical charts of 75 
patients (median age of 59 years 
ranging from 25 - 83 years) during July 
27, 2015 to August 21, 2015 as a 
preliminary study to determine the 
viability of this research. Fifty-six 
patients had complete response and 19 
had incomplete response to treatment, 
defined as evidence of disease within 6 
months. Fifty-eight patients had optimal 
cytoreductive surgery and 17 had 
suboptimal surgery. Forty-nine (65.3%) 
patients had recurrence of disease, and 
58 (77.3%) patients died. Clinical and 
pathology findings included age at 
diagnosis, body mass index, Charlson 
comorbidity index, FIGO stage, tumor 
cell type, tumor grade, preoperative 
CA125, imaging modality at diagnosis, 
and tumor location (Table 1). Imaging 
modalities used were CT, ultrasound, 
MRI, and PET scans. None of the 
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patients in this cohort received PET 
scans, 2 had MRIs and 11 had none of 
the four options. These patients were 
included under “other.” Treatment data 
included chemotherapy drug, number of 
cycles, removal of pelvic or para-aortic 
nodes at surgery, and whether the 
patient received optimal treatment 
(Table 2).  
Patient outcome was assessed by vital 
status, tumor status, time until 
recurrence, and time until death (Tables 
3-4). The Kaplan-Meier method was 
used to construct survival curves for 
overall survival (OS), cancer-specific 
survival (CSS), and time to recurrence 
(TTR) (Figure 1). For OS, time was 
calculated from date of surgery to death. 
Patients still alive were censored at date 
of last contact. For CSS, time was 
calculated from date of surgery to date 
of death due to disease. Patients still 
alive or having died from other causes 
were censored at date of last contact or 
death. respectively. For TTR, time was 
calculated from date of surgery to first 
relapse. If a patient did not experience a 
relapse, they were considered censored 
at date of last contact. 
Statistical Analysis 
To investigate treatment response and 
cytoreduction surgery differences in 
demographic, clinicopathologic, and 
outcome variables, chi-squared and t-
tests (Fisher’s exact and Wilcoxon rank 
sum tests where appropriate) were 
used. The Kaplan-Meier method was 
used to construct survival curves for 
overall survival (OS), cancer-specific 
survival (CSS), and time to recurrence 
(TTR) as aforementioned. The log-rank 
test was performed to assess for 
differences between treatment response 
and cytoreduction surgery. All statistical 
testing was two-sided and assessed for 
significance at the 5% level using SAS 
v9.4 (SAS Institute, Cary, NC).  
Results 
Characteristics of patients with complete 
and incomplete response to 
chemotherapy 
This study included 75 patients, and the 
clinical characteristics and pathology 
findings of these patients are found in 
Table 1. Fifty-six (74.7%) patients had 
complete response (CR) and 19 (25.3%) 
had incomplete response (IR) to 
chemotherapy. At diagnosis, patients 
had a mean age of 58.3 ± 12.9 years, 
median body mass index of 26 (range: 
16.5-47.8), and median Charlson index 
of 5 (range: 1-10). A significant 
difference was evidenced between 
treatment response and preoperative 
CA125. More specifically, patients 
achieving a CR had lower median 
preoperative CA125 levels compared to 
those with an IR (362.5 U/mL vs. 771.0 
U/mL; p = 0.03). One patient had a 
preoperative CA125 of 588,741 U/mL, a 
significant outlier, and was excluded 
from the analysis.
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Table 1. Clinical and pathological characteristics of treatment responses 
 
*mean ± SD, **median (range), ***N (%) 
aN = 55; complete response (CR) = 44, incomplete response (IR) = 11 
bN = 70; CR = 52, IR = 18 
cNOS, not otherwise specified 
The majority of patients were diagnosed 
at advanced stage disease. Sixty-one 
(81.3%) patients were diagnosed at 
FIGO stage III or IV, and 40 (60.6%) 
patients had tumor grade 3. No patients 
with incomplete response to treatment 
were diagnosed in stage I or II. 
However, FIGO staging, tumor cell type, 
tumor grade, imaging modality used at 
diagnosis, and tumor location were not 
significantly related to chemotherapy 
response.   
In terms of treatment as outlined in 
Table 2, both CR and IR groups had a 
median of 6 cycles of chemotherapy. 
  Treatment Response  
Covariate All Complete, N = 56 Incomplete, N = 19 p 
     Age (year)* 58.3 ± 12.9 57.5 ± 2.4 60.7 ±14.3 0.35 
BMI**, a 26 (16.5-47.8) 25.6 (16.5-47.8) 28.4 (19.3-43.3) 0.23 
Charlson index** 5 (1.0-10.0) 5 (1.0-10.0) 4 (1.0-7.0) 0.92 
Initial CA125 (U/ml)**, b 470 (20.0-32865.0) 362.5 (20.0-3917.0) 771.0 (95.0-7077.0) 0.03 
     FIGO stage*** 
              I 
              II 
              III 
              IV 
 
8 (11.0) 
4 (5.5) 
49 (67.1) 
12 (16.4) 
 
8 (14.5) 
4 (7.3) 
35 (63.6) 
8 (14.5) 
 
0 (0) 
0 (0) 
14 (77.8) 
4 (22.2) 
 
0.21 
Histology*** 
              Serous/papillary 
              Endometrioid 
              Adenocarcinoma, 
NOSc 
 
61 (81.3) 
2 (2.7) 
12 (16.0) 
 
45 (80.4) 
1 (1.8) 
10 (19.9) 
 
16 (84.2) 
1 (5.3) 
2 (10.5) 
 
0.49 
Tumor grade*** 
              1 
              2 
              3 
 
7 (10.6) 
19 (26.8) 
40 (60.6) 
 
7 (13.2) 
13 (24.5) 
33 (62.3) 
 
0 (0) 
7 (41.2) 
10 (58.8) 
 
0.21 
Imaging modality*** 
              CT only 
              Ultrasound only 
              Both 
              Other 
 
39 (52.0) 
17 (22.7) 
6 (8.0) 
13(17.3) 
 
28 (50.0) 
15 (26.8) 
5 (8.9) 
8 (4.3) 
 
11 (57.9) 
2 (10.5) 
1 (5.3) 
5 (26.3) 
 
0.35 
Tumor location*** 
              Pelvis only 
              Upper abdomen only 
              Both 
              Other 
 
38 (50.7) 
5 (6.7) 
24 (32.0) 
8 (10.7) 
 
32 (57.1) 
3 (5.4) 
15 (26.8) 
6 (10.7) 
 
6 (31.6) 
2 (10.5) 
9 (47.4) 
2 (10.5) 
 
0.18 
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Most patients were predictably treated 
with carboplatin and/or paclitaxel. A 
significantly greater frequency of 
patients who achieved CR had optimal 
treatment (60.7% vs. 26.3%; p <0.01), 
and had pelvic and/or para-aortic lymph 
nodes removed during surgery (35.7% 
vs. 10.5%; p = 0.04). The involvement of 
bowel during surgery, the achievement 
of optimal cytoreduction, and the type of 
chemotherapy drug showed no 
statistically significant differences 
between CR and IR groups. 
Table 2. Chemotherapy and surgery treatment types 
 Treatment Response  
Covariate Complete, N = 56 Incomplete, N = 19 P 
Number of cycles** 6 (0-18) 6 (1-10) 0.74 
Optimal chemotherapy*** 34 (60.7) 5 (26.3) <0.01 
Chemotherapy drug*** 
Carboplatin 
Paclitaxel 
Cisplatinum 
Other 
 
44 (78.6) 
46 (82.1) 
8 (14.3) 
16 (28.6) 
 
15 (78.9) 
13 (68.4) 
3 (15.8) 
8 (42.1) 
 
1.00 
0.21 
1.00 
0.27 
Optimal cytoreductive surgery*** 45 (80.4) 13 (68.4) 0.34 
Areas of surgery*** 
Lymph nodes 
Bowel 
 
20 (35.7) 
18 (32.1) 
 
2 (10.5) 
5 (26.3) 
 
0.04 
0.63 
*mean ± SD, **median (range), ***N (%) 
 
Association of patient outcomes with 
chemotherapy response and 
cytoreductive surgery 
Outcomes of patients in both CR and IR 
groups are represented in Table 3. 18 
(94.7%) patients with IR had tumor 
present after primary therapy. 
Significantly less patients with CR 
(57.1%) than those with IR (94.7%) had 
tumor present after therapy (p <0.01).  
In both CR and IR groups, the majority 
of patients died from ovarian cancer. 
However, significantly more patients 
with IR died from the disease than 
patients who had CR (94.7% vs. 56.4%, 
p < 0.01). More patients in the CR group 
are alive or dead from causes other than 
ovarian cancer (p <0.01). Thirty-five 
(62.5%) patients with CR had 
recurrence of disease and a median 
time to recurrence of 18.7 months 
(range: 8.9-81.5). The majority (73.6%) 
of patients with IR had recurrence; 
however the median time was 6.9 
months (range 4.3-28.6). Patients in CR 
group had a longer time until first 
recurrence of disease than the IR group 
(p < 0.01). Additionally, the survival was 
significantly longer for patients with CR 
than patients with IR (p < 0.01).  
Regarding surgical treatment, 58 
(77.3%) and 17 (22.7%) patients had 
optimal (OPS) and suboptimal (SOS) 
cytoreductive surgery, respectively, as 
shown in Table 4. The majority had 
tumor present after primary therapy for 
both groups. Nevertheless, significantly 
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more patients who underwent SOS 
(94.1%) had tumor present compared to 
patients who had OPS (58.6%, p < 
0.01). Also, more patients in the OPS 
group had no evidence of disease 
compared to patients in the SOS group 
(41.4% vs. 5.9%; p < 0.01).  
Most patients died from the disease; 
however, less patients died due to the 
disease in the OPS group than the SOS 
group (57.9% vs. 94.1%; p < 0.02). 
Patients who had OPS were significantly 
more likely to be alive (28.1% vs. 5.9%; 
p = 0.02) or died from other causes 
(14.0% vs. 0%; p < 0.02) than patients 
who had SOS.  Patients with OPS also 
had significantly longer survival (39.5 vs. 
22.0 months; p <0.05). 
Table 3.  Outcome of patients with complete versus incomplete response 
 Treatment Response  
Covariate Complete, N = 56 Incomplete, N = 19 P 
Tumor status*** 
No evidence of disease 
Tumor present 
 
24 (2.9) 
32 (57.1) 
 
1 (5.9) 
18 (94.7) 
<0.01 
Vital status*** 
Alive 
Dead from disease 
Dead from other 
 
16 (29.1) 
31 (56.4) 
8 (14.5) 
 
1 (5.3) 
18 (94.7) 
0 (0) 
<0.01 
Time until recurrence (months)**, a 18.7 (8.9-81.5) 6.9 (4.3-28.6) <0.01 
Time until death (months)**, b 50.1 (1.2-191.3) 14.9 (1.9-48.9) <0.01 
*mean ± SD, **median (range), ***N (%) 
aN = 49; CR = 35, IR = 14 
bN = 58; CR = 40, IR = 18 
Table 4. Outcome of patients with optimal versus suboptimal surgery 
*mean ± SD, **median (range), ***N (%) 
 aN = 48; optimal = 33, suboptimal = 15 
 bN = 58; optimal = 42, suboptimal = 16 
 
 
 Surgery  
Covariate Optimal, N = 58 Suboptimal, N = 17 P 
Tumor status*** 
            No evidence of disease 
           Tumor present 
 
24 (41.4) 
34 (58.6) 
 
1 (5.9) 
16 (94.1) 
 
<.01 
Vital status*** 
            Alive 
            Dead from disease 
            Dead from other 
 
16 (28.1) 
33 (57.9) 
8 (14) 
 
1 (5.9) 
16 (94.1) 
0 (0) 
 
0.02 
Time until recurrence (months)**, a 14.7 (4.3-70.7) 14.4 (6.3-81.5) 0.84 
Time until death (months)**, b 39.5 (1.5-191.3) 22.0 (1.2-118.4) 0.05 
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Survival analysis 
The Kaplan-Meier analyses to assess 
overall survival (OS), cancer-specific 
survival (CSS), and time to recurrence 
(TTR) are shown in Figures 1 and 2, 
and Tables 5 and 6. Patients who had 
complete treatment response had 
significantly increased OS, CSS, and 
TTR (p < 0.01 for all). Patients who had 
optimal surgery also had significantly 
higher OS, CSS, and TTR than patients 
with suboptimal surgery (p < 0.01 for 
all).
 
 
 
 
Figure 1. Kaplan-Meier analysis of overall survival, cancer-specific survival, and 
time to recurrence between patients with complete and incomplete response to 
treatment. Significant difference exists between both groups in all three 
categories (p < 0.01), and median time of survival is presented in Table 5. 
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Table 5. Survival analysis for patients with complete and incomplete response 
 
 
 
Figure 2. Kaplan-Meier analysis of overall survival, cancer-specific survival, and 
time to recurrence between patients with optimal and suboptimal surgery. 
Significant difference exists between both groups in all three categories (p < 
0.01), and median time of survival is presented in Table 6.   
 Treatment response  
Median time (months) Complete Incomplete P 
Overall survival 68 15 <0.01 
Cancer specific survival 79 15 <0.01 
Time to recurrence 36 7 <0.01 
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Table 6. Survival analysis for patients with optimal and suboptimal surgery 
 
Discussion 
Standard treatment of epithelial ovarian 
cancer is primary debulking surgery in 
conjunction with platinum-based 
chemotherapy. Despite the success of 
chemotherapy, about one-third of 
women are either refractory or resistant 
to treatment. Preoperative CA125 and 
lymph node removal during surgery 
were associated with complete 
treatment response in this preliminary 
institutional study. 
CA125 as a predictor of chemotherapy 
response  
CA125 is a biomarker of epithelial 
tumors that is useful as a measure for 
monitoring treatment effectiveness and 
disease recurrence. It is not 
recommended as a tool for screening. In 
our study, preoperative CA125 is a 
significant predictor of chemotherapy 
response. Patients with complete 
response to treatment had significantly 
lower CA125 at diagnosis, and complete 
response to treatment had significantly 
greater overall survival, cancer-specific 
survival, and time to recurrence. Many 
studies both support and contradict this 
finding. A study by Oikonomopoulou et 
al. agrees that lower baseline CA125 
prior to chemotherapy is associated with 
better chemotherapy response. Higher 
baseline values had worse OS and 
PFS.5 Similarly, Palmer et al. and 
Juretzka et al. found lower CA125 were 
more significantly associated with longer 
overall survival and progression-free 
survival.6,7 Serum CA125 levels 
correlate with vascular endothelial 
growth factor (VEGF) expression, which 
is significantly upregulated in epithelial 
ovarian cancer, and predicts positive 
responsiveness to platinum-based 
chemotherapy.8 
The debate continues as other studies 
discovered no correlation between 
preoperative CA125, chemotherapy 
response, and surgical outcome despite 
being a validated marker for disease 
status during chemotherapy.8,9,10 The 
role of CA125 as a predictor marker for 
chemoresponsiveness may be 
appropriate with newer chemotherapy. 
Collinson et al. suggests that CA125 
can identify patients with epithelial 
ovarian cancer who will likely respond to 
bevacizumab.11 When patients are 
treated with standard chemotherapy and 
bevacizumab concurrently and then via 
maintenance, patient with high CA125 
and ascites have improved overall 
survival and progression-free survival 
than patients with lower CA125 and 
without ascites.12 Albeit higher levels of 
CA125 are associated with worse 
patient outcome, the threshold value or 
 Surgery  
Median time (months) Optimal Suboptimal P 
Overall survival 60 22 <0.01 
Cancer-specific survival 78 22 <0.01 
Time to recurrence 24 14 <0.01 
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range to determine which patients are at 
increased risk for incomplete response 
to chemotherapy is unknown. 
Complete chemotherapy response and 
optimal surgery in controlling disease 
Complete response to therapy and 
optimal cytoreductive surgery are two 
important factors associated with a 
decrease in death from disease and 
longer survival. Over 94% of patients 
with either incomplete treatment 
response or suboptimal surgery died 
from ovarian cancer. This value lowered 
significantly to less than 60% death from 
disease those with either complete 
treatment response or optimal surgery. 
Additionally, patients with complete 
treatment or optimal surgery had longer 
time until death and recurrence, greater 
overall survival, and greater cancer-
specific survival of up to over 5-fold 
increase. The increase in median 
survival time and time to recurrence was 
greater in terms of chemotherapy 
response than for surgery. Although 
both surgery and chemotherapy are key 
components to treating ovarian cancer, 
this suggests that chemotherapy has a 
greater role in prolonging survival and 
recurrence.  
Our study also found that patients with 
complete response to therapy were 
more likely to have either pelvic and/or 
para-aortic lymph nodes removed during 
surgery. The spread of disease to the 
retroperitoneal lymph nodes is a 
prominent characteristic of advanced 
stage ovarian cancer. Although FIGO 
stage did not differ between the 
response groups, patients with complete 
treatment response more frequently had 
surgery to the nodal areas than patients 
with an incomplete response. 
Involvement of the bowel during surgery 
showed no significant associations with 
the two response groups. In a recent 
review by Chang et al. discussing 
cytoreduction on advanced stage 
ovarian cancer, aggressive surgery is 
prognostic of better outcomes, but 
optimal debulking is dependent on 
expertise of the surgeon and of the 
institution.13 This study was completed 
at a teaching hospital with a department 
of gynecologic oncology and specialized 
surgeons. Therefore, these findings may 
be specific to this institution.  
Limitations  
The limitations of this study are due to 
the retrospective nature of the analysis. 
Additionally, there may be not sufficient 
power to establish significances in this 
preliminary analysis. The incomplete 
response group represented 25.3% of 
the patient sample and the suboptimal 
surgery group represented 22.7%. Thus, 
the power should increase as more 
patients are added to this study. 
Future direction 
The current conflicting 
clinicopathological data pushes us to 
look deeper into genomic factors that 
may help us better understand how to 
predict chemoresponsiveness. In future 
studies, we will look at possible 
molecular predictors. The existing 
literature has assessed the predictive 
value of tumor markers such as human 
epididymis protein 4 (HE4), a 
glycoprotein overexpressed in serous 
and endometrioid ovarian cancers. 
Serum HE4 levels were not found to be 
a predictor of chemoresponse prior to 
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treatment, but its normalization during 
treatment was significantly associated 
with positive outcomes.9,14 More 
recently, Muallem et al. found that the 
level of ERCC1, a DNA excision repair 
protein, was significantly associated with 
better overall survival. Patients who did 
not respond to platinum-based 
chemotherapy with low or intermediate 
ERCC1 levels had a longer overall 
survival than non-responders with high 
ERCC1.15 Steffensen et al. furthermore 
suggest that high ERCC1 expression is 
associated with earlier time to 
recurrence and platinum-resistance.16 
Lastly, other proteins, such as E-
cadherin, interferon regularly factor 1 
(IRF1), and high-temperature-required 
protein A2 (HtrA2) have been shown to 
be prognostic and associated with 
increased response to platinum-based 
chemotherapy at higher levels of 
expression.17,18,19 These specific 
proteins may be subjects of future 
evaluation in this institutional study. 
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